ALL-REZ Registry

Relapse of acute lymphoblastic leukaemia

Registry

• If possibly, complete registration of all children and adolescents with a first or further relapse of ALL who do not participate in an IntReALL trial
• Continuation of etablished refererence diagnostics and biobanking
• Ensuring long-term follow-up of patients

Recording all children and adolescents with an ALL recurrence as completely as possible in a registry will allow epidemiological statements on the incidence, course and prognosis of this group of patients, which contributes like no other to the mortality of children/adolescents with malignant diseases. Patients can be followed up systematically. Late effects can be recorded and correlated with previous therapies and clinical factors, corresponding risks considered in future treatment strategies. As a competence center for relapsed/refractory ALL, the study center can advise participating centers on specific questions regarding individual treatment strategies as well as radiation and transplant indications. Patients with relapsed and/or refractory ALL can be advised on treatment in an open AMG trial and assigned accordingly.

The treatment instructions attached to this protocol in this specific form and combination do not represent recommendations for a generally recognized treatment, but are rather guidelines for treatment.
The risk groups S1 to S4 are classified according to the definition of the ALL-REZ BFM 2002 study. Only change to this classification is the categorization of very early isolated extramedullary recurrences into the S4 group. Due to the good results achieved in the ALL-REZ BFM 2002 trial, treatment according to this protocol is still recommended for children and adolescents with 1st ALL recurrence until the start of the new international ALL relapse study. Consolidation is performed according to protocol II-Ida. In case of a subsequent relapse, consultation with the study center is recommended.

• Diagnosis of a ALL relapse (B-precursor or T, isolated or combined medullary or eytramedullary)
• Registry:
• written informed consent
• Tumorbanking:
• written informed consent to tumorbanking and accompanying biological research